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Abstract: The Epidermal Growth Factor Receptor (EGFR) is the prototypical receptor tyrosine kinase (RTK). These cell 
surface receptors are integral membrane proteins that bind ligands on their extracellular domain and relay that information 
to within the cell. The activated EGFR regulates diverse cell fates such as growth, proliferation, differentiation, migration, 
and apoptosis. These signaling properties are important for the appropriate development and maintenance of an organism. 
However, when inappropriately controlled, due to EGFR overexpression or hyperactivation, these signaling events are 
characteristic of many cancers. It remains unclear whether the uncontrolled EGFR activity leads to cell transformation or 
is a consequence of cell transformation. Regardless of the cause, increased EGFR activity serves both as a biomarker in the 
diagnosis of some cancers and is a molecular target for anti-cancer therapies. The promising results with current anti-EGFR 
therapies suggest that the receptor is a viable molecular target for a limited number of applications. However, to become an 
effective therapeutic target for other cancers that have elevated levels of EGFR activity, current approaches for inhibiting 
EGFR signaling will need to be reﬁ  ned. Here we describe the molecular mechanisms that regulate EGFR inactivation and 
discuss their potential as therapeutic targets for inhibiting EGFR signaling.
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The ErbB Family
The EGFR, or ErbB-1, is one of four members of the ErbB family that also includes ErbB-2, ErbB-3 
and ErbB-4 (Carpenter, 2003; Citri et al. 2003). The EGFR is expressed as a monomeric 1186 amino 
acid transmembrane protein with approximately half of the protein extracellular (621 amino acids) 
(Ullrich et al. 1984). The receptor contains three important regions  —the extracellular ligand binding 
domain, a transmembrane-anchoring domain, and an intracellular intrinsic kinase domain (Chinkers 
and Brugge, 1984; Downward et al. 1984a). The other ErbB family members are structurally similar, 
but differ in their preference for ligands, ability to associate with other family members, tissue distribu-
tion, and signaling properties (Wiley, 2003).
Activation of the EGFR is dependent on binding ligand in the extracellular space that has been 
secreted in either an autocrine or paracrine manner (Fig. 1). There are six unique endogenous ligands 
for the EGFR helping generate diverse signals: EGF, transforming growth factor α (TGF-α) heparin-
binding EGF (HB-EGF), amphiregulin, betacellulin, and epireglin (Harris et al. 2003). These ligands 
differ from one another in their regulated secretion, tissue distribution, and binding properties. Studies 
in which speciﬁ  c ligands have been ablated, either surgically or genetically, indicate that often one 
ligand can compensate for another (Tsutsumi et al. 1987). When three different ligands (EGF, TGF-α, 
and amphiregulin) were simultaneously knocked out of C57 black mice, there were defects in the skin, 
eye development, mammary gland development, and coat hair. When only one or two of the three 
ligands were ablated, there were only subtle phenotypes. One of which was mammary gland develop-
ment when amphiregulin was knocked out in conjunction with TGFα or EGF (Luetteke et al. 1999). 
These ﬁ  ndings suggest there are complementary roles for these ligands and underscore the difﬁ  culty in 
understanding receptor physiology in the context of a whole animal.
The EGFR is expressed in a variety of tissues (Yano et al. 2003). The EGFR is also critical to the 
development of tissues of epithelial, mesenchymal, and neuronal origin. EGFR knockout mice have 
been bred from different genetic backgrounds, showing either embryonic or postnatal lethality with 48
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multiple organ defects (Miettinen et al. 1995; 
Sibilia and Wagner, 1995). These ﬁ  ndings point to 
the essential role of the EGF receptor in the devel-
opment and tissue homeostasis of organisms in 
which it is expressed. Thus, the complete loss of 
EGFR function is deleterious to the organism.
EGFR Activation
Ligand binding initiates receptor activation by 
inducing a conformational change and allowing 
for dimerization of two EGF receptor monomers 
(Ferguson et al. 2003). Dimerization leads to trans-
phosphorylation of tyrosine residues on the cyto-
plasmic tail of one receptor by the intracellular 
kinase domain of the corresponding dimer 
(Lammers et al. 1990). Tyrosine phosphorylation 
is the essential activation step in EGFR signal 
transduction as these residues serve as docking 
sites for downstream signaling molecules contain-
ing Src homology 2 (SH2) or phosphotyrosine 
binding (PTB) domains. Signaling pathways 
activated by the EGFR include the phosholipase 
C gamma (PLCγ), mitogen-activated protein kinase 
(MAPK), and phosphatidylinositol 3 kinase 
(PI3K), Signal Transducers and Activators of 
Transcription 3 (STAT3) and Akt pathways (Yarden 
and Sliwkowski, 2001). The activities and bio-
chemical changes induced by these signaling 
pathways integrate to mediate the speciﬁ  c modula-
tion in cell biology such as cell growth, prolifera-
tion, differentiation, migration, and regulation of 
apoptosis (Jorissen et al. 2003).
EGFR and Cancer
The ﬁ  rst link between EGFR and malignant trans-
formation came from studies that showed the 
EGFR is a homolog of the avian erythroblastosis 
virus v-erbB oncogene (Downward et al. 1984b). 
Several years later, a direct link between increased 
signaling from the EGFR and malignant growth 
Figure 1. Schematic of EGFR activation. Inactive EGFR exist as monomers on the plasma membrane. Upon binding of one of six endog-
enous ligands, two monomers dimerize and activate the receptor’s intrinsic kinase domain. The active kinase domain of one EGFR monomer 
transphosphorylates tyrosine residues on carboxyl terminus of its receptor pair. Once activated, the phosphotyrosines serve as docking site 
for downstream effectors, which include enzymes, adaptor proteins, and other regulatory molecules. Signaling from effectors integrates to 
modulate cell physiology, some of which are indicated. Phosphatidyl inositol 3-kinase (PI3K), phospholipase Cγ (PLCγ), signal transducers 
and activators of transcription 3 (STAT3), Growth factor receptor-bound protein 2 (Grb2), Src homology containing protein (Shc), p120 ras 
GTPase activating protein (P120), phosphatase B (PTB), cellular sarcoma (c-Src), and Abl.49
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was found in Epstein-Barr virus infected cells, a 
condition already known to lead to epithelial malig-
nancies (Miller et al. 1995). Clinical studies pro-
vided supporting evidence that many human 
tumors and cell lines derived from human tumors 
overexpress EGFRs. Together, these data pointed 
to a potential role for the EGFR in tumor formation 
(Libermann et al. 1985; Merlino et al. 1984; 
Yamamoto et al. 1986). The hypothesized link 
between EGFR and cancer was strengthened when 
in vitro studies showed infection of NIH-3T3 cells 
with either retrovirus encoding EGFR, or a eukary-
otic vector encoding EGFR cDNA, induced a 
transformed phenotype (Di Fiore et al. 1987; Velu 
et al. 1987).
EGFR overexpression and/or hyperactivation 
is associated with a number of cancers such as 
breast, ovary, renal, non-small cell lung, head and 
neck, colorectal, pancreatic, prostate, cervical and 
bladder (Sebastian et al. 2006). Overexpression is 
used as an indicator of poor prognosis in breast, 
ovarian, and head and neck cancers (Fischer-
Colbrie et al. 1997; Ishitoya et al. 1989; Magne 
et al. 2001; Sebastian et al. 2006). In the clinic, 
increased EGFR expression has also been impli-
cated with resistance to hormonal therapies in 
advanced stage breast cancers (Newby et al. 
1997).
Although, it remains controversial as to whether 
EGFR overexpression is the cause of the cancer or 
a secondary consequence, the strong association 
between the EGFR and cancer has made it a natural 
candidate as an anti-cancer chemotherapeutic. 
Enhanced EGFR signaling can arise from a variety 
of mechanisms including receptor overexpression, 
mutations leading to constitutive activation, 
increased ligand production, or defective inactiva-
tion (Zandi et al. 2007). Early studies by Haigler 
and Carpenter indicated that in cultured cells, inhi-
bition of ligand binding with an EGFR speciﬁ  c 
antibody could prevent DNA synthesis (Haigler and 
Carpenter, 1980). Since then, the EGFR has been a 
major molecular target in the treatment of cancer.
Current EGFR-Targeted Inhibition 
Strategies
From the work in tissue culture, two strategies have 
emerged for inhibiting uncontrolled cell growth 
arising from EGFR overexpression or hyperactiva-
tion—monoclonal antibodies (MAbs) and tyrosine 
kinase inhibitors (TKIs). These approaches share 
the same goal of inhibition of receptor activity but 
differ in their molecular mechanism. MAbs target 
the extracellular portion of the receptor whereas the 
TKIs inhibit the intracellular portion. Multiple 
drugs from each class have been approved by the 
FDA for the treatment of certain types of cancers.
There are two monoclonal antibodies that have 
approval from the Food and Drug Administration 
(FDA)—Cetuximab (Erbitux) [February 2004] and 
Vectibix (Panitumumab) [September 2006]. These 
antibodies are used therapeutically for the treat-
ment of metastatic colorectal cancer and cancers 
of the head and neck. Both Cetuximab and Vectibix 
inhibit binding of ligands to the EGFR causing a 
decrease in basal and ligand mediated receptor 
activation (Harari et al. 2007; Huang et al. 1999; 
Moroni et al. 2005) . The decreased receptor activ-
ity inhibits cell growth, induces apoptosis, and 
decrease the production of other cellular factors 
associated with cancer progression and metastasis, 
such as matrix metalloproteinases, and vascular 
endothelial growth factor (Astsaturov et al. 2006; 
Zhu, 2007). Currently, the MAbs are used in com-
bination with other agents or alone when the can-
cer is refractory to standard therapy.
The other class of EGFR inhibitors, TKIs, are 
small molecules that block EGFR activity by com-
peting with ATP for use as a substrate by the 
receptor’s intrinsic kinase domain. The FDA has 
approved two EGFR-specifc TKIs, Iressa 
(Geﬁ  tinib) [December 2004] and Tarceva (Erlo-
tinib) [November 2004], for the treatment of non-
small cell lung carcinoma (Morgillo et al. 2007). 
A third FDA-approved drug, Lapatinib, can inhibit 
the kinase activity of both the EGFR and ErbB2. 
Lapatinib is used in combination with Herceptin 
for the treatment of HER2/neu positive breast 
cancers that are resistant to other therapies (Moy 
et al. 2007). Like the MAbs the mechanism of 
action for the TKIs is to block the activation of 
downstream signaling pathways. Interestingly, 
Geﬁ  tinib has been shown to be most effective in 
~10% of non-small cell lung carcinoma patients 
with mutations around the ATP binding domain of 
the EGFR (Lynch et al. 2004).
Additional strategies targeting the EGFR focus 
on the rate at which new receptors are made and 
target the mRNA that encodes the EGFR. These 
approaches include EGFR-speciﬁ  c RNA interfer-
ence (O’Grady et al. 2005), antisense oligonucle-
otides (Melisi et al. 2004), and ribozymes (Yamazaki 
et al. 1998). While these are effective approaches 50
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in tissue culture models, the methodology for 
delivering RNAi, oligonucleotides, and ribozymes 
to patients requires further development.
Limitations of the Current
Therapies that Target the EGFR
It should be noted that there are some restrictions to 
the FDA approved drugs that inhibit EGFR signal-
ing and cancer growth. First, despite the wide range 
of cancers that are characterized by EGFR overex-
pression and/or hyperactivation, these drugs have 
only been approved for a limited number of cancers. 
However, both classes of drugs are currently enroll-
ing patients in Phase 2 and Phase 3 trials for the 
treatment of other EGFR positive cancers, such as 
cervical, skin, myelogenous leukemia, prostate and 
glioblastomas (ClinicalTrials.gov, 2007).
Second, MAb and TKI therapies have numerous 
unpleasant side effects. Dermatological (rash, light 
sensitivity, and acne) and gastrointestinal (diarrhea, 
loss of appetite, and nausea) side effects have been 
reported for both therapeutic approaches (Rocha-
Lima et al. 2007). Since proper EGFR function is 
required for normal skin and gastrointestinal muco-
sal regeneration (Grazul-Bilska et al. 2003; Jones 
et al. 1999), these toxicities are in all likelihood 
due to EGFR inhibition and aberrant EGFR-
mediated regulation of tissue homeostasis.
Novel Targets for Attenuating 
EGFR Signaling in Cancer
The treatment of patients with tumors that overex-
press EGFRs could beneﬁ  t from novel methods of 
inhibiting EGFR signaling. Alternative approaches 
to targeting the EGFR need to take into consider-
ation the empirically determined strengths and 
weaknesses of the current therapies.
Rather than inhibit the activation of the EGFR, 
an alternative approach would be to accelerate the 
rate of receptor inactivation. Strategies to attenuate 
the activated EGFR in cancers by accelerating the 
endocytic process have been largely overlooked. 
Components of the endocytic pathway could be 
stimulated to accelerate the normal rate of signal 
attenuation. At this time, there are no agents under 
consideration, but that likely reﬂ  ects the lack of 
molecular details regarding the EGFR signal ter-
mination and which molecules would be the best 
candidates.
Despite the incomplete understanding of this 
process, there are some obvious advantages to this 
strategy. By decreasing the duration of the active 
EGFR, the signaling necessary for cellular homeo-
stasis would still be permitted while uncontrolled 
cell growth and replication would be inhibited. 
Second, those cells with the highest levels of recep-
tor expression and/or activity would be affected the 
most. Third, by targeting receptor inactivation, there 
is no discrimination between uncontrolled cell 
growth that arises due to receptor overexpression 
versus receptor hyperactivation. This may allow 
such compounds have a broader applicability.
Below we discuss four potential mechanisms for 
signal termination of the activated EGFR from 
within the endocytic pathway: 1) dissociation of 
the ligand:receptor complex, 2) phosphatase-
mediated receptor dephosphorylation 3) sequestra-
tion of the activated EGFR from effector molecules, 
and 4) lysosomal degradation of the receptor 
(Fig. 2). These molecular mechanisms have been 
shown to be effective ways of attenuating EGFR 
signaling in tissue culture models, but it remains 
unclear which ones are physiologically important. 
Nevertheless, at this point, they all remain as viable 
pharmacological targets. This discussion will 
include the pros and cons of each mechanism.
EGFR Endocytic Trafﬁ  cking
Ligand binding mediates two related functions. 
First, as mentioned above, is the initiation of down-
stream signaling pathways. Second, the ligand:
receptor complex is internalized. This process, 
termed endocytosis, reduces the amount of recep-
tor available for ligand binding on the cell surface 
as well as inactivates the receptor through dephos-
phorylation and/or receptor degradation. In addi-
tion, the internalization of the receptor physically 
moves the receptor through various endocytic 
compartments, and thereby changes the down-
stream effectors with which it has contact. Ligand-
mediated receptor endocytosis has historically been 
overlooked as a molecular mechanism to attenuate 
the signaling of the EGFR.
There is a steady-state cycle in which the EGFR 
is slowly internalized (~1%–2% of the total receptor 
population/min) and rapidly recycled to the cell 
surface (Lund et al. 1990). However, ligand bind-
ing accelerates this process and induces a more 
dramatic redistribution of the receptor from the 
plasma membrane and directs the activated EGFR 
to the lysosome for degradation (Fig. 2). The EGFR 
is the only member of the ErbB family shown to 51
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undergo ligand-mediated internalization. In cells 
that express multiple ErbB family members, recep-
tors that heterodimerize with the EGFR prevent 
endocytosis of the entire ligand:receptor complex 
(Baulida et al. 1996, Lenferink et al. 1998).
At the plasma membrane, ligand-bound EGFRs 
move laterally along the cell surface to a plasma 
membrane domain whose intracellular face is 
enriched with clathrin. The membrane domain 
invaginates to give rise to a clathrin-coated pit 
that eventually pinches off to form a clathrin-
coated vesicle containing the ligand:receptor 
complex. Once inside the cell, the clathrin is shed 
from the vesicle and is now referred to as a pri-
mary endocytic vesicle. This vesicle fuses with 
the early endosome, and delivers the EGF:EGFR 
complex. Through endosomal maturation, the 
cargo arrives in a second endosomal compartment 
often referred to interchangeably as the multive-
sicular body (MVB) or late endosome. During 
Figure 2. Ligand stimulated EGFR Endocytic trafﬁ  cking (indicated by solid arrows). Ligand stimulation accelerates the rate of EGFR 
internalization via clathrin-coated pits. Following invagination and pinching off, the resulting clathrin-coated vesicle sheds its clathrin and 
delivers its cargo to the early endosome. In the early endosome, the cargo is sorted for delivery to its appropriate cellular location. In most 
cases, the EGFR is delivered to the lysosome for degradation. Early endosome matures into a late endosome/multiviesicular body (MVB). 
The contents of the late endosome/MVB are delivered to a lysosome for degradation. Indicated with dashed arrows are other possible routes 
of endocytic trafﬁ  cking. A small percentage of total EGFR internalizes via clathrin-coated pits in a ligand independent manner (~1%–2%/min). 
In addition, unliganded EGFR will trafﬁ  c from the early endosome to the plasma membrane via a recycling endosome upon ligand 
dissociation.52
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this maturation, membrane structures form in the 
lumen, called intralumenal vesicles. In these 
internal vesicles, the EGFR is oriented such that 
the carboxyl terminal phosphotyrosines no longer 
have access to effector proteins. Finally, cargo is 
transferred to the lysosome by fusion of the endo-
some with lysosome, and degraded in the acidic, 
protease rich environment (Sorkin and von 
Zastrow, 2002).
Ligand-mediated endocytosis has always been 
recognized as a means of regulating EGFR signal-
ing, but the mechanisms of regulation are still being 
discovered. Early studies by Wells et al. used trun-
cation mutants of the EGFR that retained the abil-
ity to signal, but could not internalize. NIH 3T3 
cells expressing these mutants underwent EGF-
dependent cell transformation/mitogenesis at lower 
doses (Wells et al. 1990). From these data, it was 
concluded that internalization of the EGFR played 
a role in attenuating EGFR-mediated responses. 
This idea was challenged by Vieira et al. when they 
inhibited EGFR internalization using a dominant 
negative mutant of the large GTPase, dynamin. 
Dynamin regulates the internalization of clathrin-
coated pits, and the expression of dominant nega-
tive dynamin allowed activation of the EGFR and 
retention at the plasma membrane. In these exper-
iments, it was determined that full activation of 
MAPK and PI3-K could not be achieved if the 
receptor were retained on the cell surface. Con-
versely, the activity of some effectors (i.e., PLCγ 
and Shc) was enhanced by cell surface retention 
of the receptor. Thus, receptor internalization both 
positively and negatively regulates signaling 
(Vieira et al. 1996).
The compartmentalization of the EGFR as it 
moves through the endocytic pathway provides 
additional mechanisms to regulate receptor:effec-
tor interactions. It remains to be seen whether the 
signaling from a given endocytic compartment can 
be attributed to a speciﬁ  c cell physiology. If this 
does prove to be the case, inhibition of EGFR 
signaling from distinct cellular locations may be a 
new way to modulate receptor response.
Ligand:Receptor Dissociation
Within 5–10 minutes of ligand stimulation, the 
ligand:receptor complex enters the cell and trafﬁ  cs 
to the early endosome. The early endosome, as well 
as all subsequent endosomes, is characterized by its 
increasingly acidic environment. The early endosome 
is recognized as a point of sorting in the cell where 
cargoes are directed to a variety of cellular locations 
such as the late endosome, endoplasmic reticulum, 
or to the plasma membrane. For the EGFR, it has 
been shown that all three routes are viable options 
and dependent on the cell type. However, ligand-
stimulated EGFR degradation is a saturable process, 
and trafﬁ  cking to the lysosome may be the primary 
destination of the ligand:receptor complex in cells 
with the physiologic levels of receptor and trafﬁ  cking 
proteins (French et al. 1994; Mizuno et al. 2005). 
Similarly, recycling of the stimulated EGFR back 
to the plasma membrane may be the consequence 
of receptor overexpression (Masui et al. 1993). 
Targeting to the ER and onto the nucleus is a 
relatively new model, but has been shown in 
multiple cell lines and affects the transcription of 
cyclin D, and important regulator of cell cycle 
regulation (Liao and Carpenter, 2007).
The molecular mechanisms of some aspects of 
early endosomal sorting have been well-
established. Binding of ligand to the EGFR is pH 
sensitive, with optimal binding occurring at 
physiological pH and dissociation occurring at 
lower pHs. The lower pH of the early endosome 
can cause dissociation of the receptor from the 
ligand. However, all ligand:EGFR interactions are 
not affected equally by pH. For instance, TGF-α 
is more sensitive to the early endosome pH and 
therefore dissociates more readily in the early 
endosome (Korc and Finman, 1989). Once free of 
ligand, the receptor becomes rapidly desphos-
phorylated, thereby inhibiting interactions with 
downstream effectors, such as c-Cbl (Lenferink 
et al. 1998). In the absence of c-Cbl association 
and receptor ubiquitylation, the receptor is not 
properly targeted to the lysosome for destruction 
and instead recycles to the plasma membrane. 
Thus, the TGF-α:EGFR dissociation induced in 
the early endosome has the immediate conse-
quence of receptor inactivation, but the potential 
for multiple rounds of receptor activation and 
enhanced signaling.
If one considers the models of compartmental-
ized signaling, a strategy of ligand:receptor dis-
sociation may be effective for inhibiting EGFR 
signals from the late endosome/MVB, as the acti-
vated complex would never enter that compart-
ment. To date, it has not been shown that unique 
or signiﬁ  cant signaling originates from the late 
endosomes, although this remains a formal pos-
sibility. Overall, ligand:receptor dissociation has 53
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limited potential as a mechanism for inhibiting 
EGFR signaling, unless additional measures could 
be taken to ensure the unbound receptor were tar-
geted for degradation.
Inactivation by Protein Tyrosine 
Phosphatases
A second mechanism by which EGFRs are inacti-
vated is the catalyzed de-phosphorylation of the 
receptor by phosphatases. The discovery of 
protein-tyrosine phosphatases (PTP) came several 
years after that of tyrosine kinases, but they were 
immediately recognized as important regulatory 
components of signaling (Tonks et al. 1988). Dis-
ruption of the reciprocal interactions between 
kinases and phosphatases can result in dramatic 
changes in cell physiology (Tonks and Neel, 2001). 
All PTPs share a central catalytic domain, while 
the differences in their amino and carboxy terminus 
confer unique cellular locations and binding part-
ners (Barford et al. 1995). PTPs dephosphorylate 
substrates through the formation of a covalent bond 
between a phosphatase cysteine residue and the 
substrate phosphate followed by hydrolysis (Cirri 
et al. 1993; Zhang and VanEtten, 1991).
There are approximately 100 members of the 
PTP superfamily. Thirty-eight (38) comprise 
the “classical” tyrosine-only speciﬁ  c subfamily, and 
the remainder belonging to the dual speciﬁ  city 
phosphatases (DSPs) which de-phosphorylate 
tyrsosine, threonine or serine residues (Tonks, 
2006). To date, more is known about tyrosine phos-
phatase regulation of EGFR signaling than regula-
tion by dual specificity phosphatases. The 
tyrosine-only phosphatases can be further divided 
into the transmembrane receptor-like PTPs and the 
intracellular non-receptor PTPs (Andersen et al. 
2004). Both receptor and non-receptor tyrosine 
phosphatases have been shown to directly regulate 
EGFR activity (Suarez Pestana et al. 1999; Tomic 
et al. 1195). This regulation can occur at multiple 
levels: by choice of protein substrate (receptor), 
recognition sequence, and subcellular localization.
The development of “substrate-trapping” 
mutants of phosphatases has proved to be an 
invaluable tool for identifying speciﬁ  c substrates. 
Through mutation of either critical residues of the 
active site (cysteine) or the catalytic domain 
(asparigine), these mutants overcome the transient 
nature of the enzyme-substrate complex to retain 
high affinity binding of phosphatases to their 
substrates (Flint et al. 1997). These mutatants were 
key in the identiﬁ  cation of the EGFR as a substrate 
for numerous phosphatases. Substrate trapping 
mutants were expressed in COS1 cells and used to 
co-immunoprecipitate the T-cell protein tryosine 
phosphatase (TCPTP) and the EGFR. Subsequently 
it was shown that overexpression of transfected 
TCPTP, but not the substrate-trapping mutant, 
dephophorylated the receptor in an EGF-dependent 
manner, indicating the presence of a regulatory 
feedback mechanism (Tiganis et al. 1998). In a 
subsequent study in COS1 cells, TC45, the nuclear 
form of TCPTP, was transiently overexpressed and 
examined for effects on EGF-induced activation 
of speciﬁ  c signaling pathways. Overexpression of 
TC45 caused a decrease in EGFR phosphorylation 
and reduced signaling to downstream effectors, 
namely PI3-K- mediated activation of Akt (Tiganis 
et al. 1999). Similarly, in U87MG cells, a 
glioblastoma-astrocytoma cell line that normally 
expresses low levels of TC45, stable overexpres-
sion of TC45 negatively regulates the receptor and 
decreased both Akt and MAPK signaling (Klingler-
Hoffmann et al. 2001). Together, these studies 
illustrate how the targeted dephosphorylation of 
the EGFR can decrease the activity of effectors 
that lead to cell growth.
The speciﬁ  city of a phosphatase can also be 
intramolecular. The existence of site-specific 
phosphatases that differentially dephosphorylate 
particular phospho-tyrosines on the carboxy 
terminus of the EGFR is well established. The loss 
of these phosphotyrosines allows for regulation of 
individual EGFR signaling pathways. Using the 
previously described substrate-trapping mutants, 
the direct association between receptor-type 
protein-tyrosine phosphatase-κ (RPTP-κ) and the 
EGFR was demonstrated when the two proteins 
were co-expressed in Chinese Hamster Ovary cells 
which do not normally express either protein. The 
RPTP-κ has been shown in vitro to rapidly dephos-
phorylate EGFR at phosphotyrosine residues 1068 
and 1173, but not phosphotyrosine 992. While 
overexpression of RPTP-κ in human keratinocytes 
led to decreased levels of phosphorylated EGFR 
and growth, RNAi mediated knockdown had the 
reciprocal effect of increasing basal and EGF-
mediated phosphorylation levels and MAPK 
activity (Xu et al. 2005).
Tyrosine-residue speciﬁ  c dephosphorylation has 
also been identiﬁ  ed for the non-receptor SH2-
domain containing PTPs, SHP-1, and SHP-2. 54
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SHP-1 associates directly with the EGFR in human 
mammary carcinoma cells through phosphotyro-
sine 1173 on the EGFR (Keilhack et al. 1998; 
Tomic et al. 1995), while SHP-2 mediates the 
dephosphorylation of tyrosine 992 (Agazie and 
Hayman, 2003). Overexpression of SHP-1 in 
human epithelial cells led to the downregulation 
of MAPK activity, while expression of the tyrosine 
1173 to phenylalanine mutant (Y1173F) EGFR 
mutant, prevents SHP-1 binding to the receptor, 
and leads to enhanced EGFR-mediated MAPK 
signaling (Keilhack et al. 1998).
The third mechanism by which phosphatase 
activity is regulated is by restriction of its cellular 
distribution, thereby controlling where in the cell 
EGFR signaling is terminated. By adding back 
a ﬂ  uorescently-tagged, catalytically inactive PTPB1 
mutant to PTP1B-/- mouse ﬁ  broblasts, Haj et al. 
were able to determine the subcellular localization 
at which the modiﬁ  ed phosphatase associated with 
a GFP-tagged EGFR (Haj et al. 2002). As expected, 
the ligand-stimulated GFP-EGFR internalized. Once 
inside the cell, the EGFR trafﬁ  cked to the ER where 
PTPB1 association was determined by Fluorescence 
Energy Transfer (FRET). The authors propose this 
to be the site of dephosphorylation, and suggest this 
occurs prior to the EGFR being targeted to the 
lysosome. The authors speculate that there may be 
“dephosphorylation compartments” at other loca-
tions within the cell. Intriguingly, they propose that 
endocytosis of the receptor may potentiate signaling 
by removing the receptor from plasma membrane 
localized PTPs.
It is important to note that increases in phos-
phatase activity are not always associated with 
decreased EGFR signaling. Increased phosphatase 
activity can also positively regulate EGFR 
signaling. For instance it has been shown than 
SHP-2 speciﬁ  cally dephosphorylates phosphoty-
rosine 992 of the EGFR (Agazie and Hayman, 
2003). Interestingly, the Drosophila homolog of 
SHP-2 dephosphorylates the binding site for the 
SH2 domain of the Ras GTPase activating protein 
(RasGAP), which hydrodylzes GTP bound Ras to 
GDP Ras. Therefore, positive regulation of EGFR 
through inhibiting the activity of a negative regu-
lator of downstream EGFR signaling seems the 
most likely mechanism of SHP-2’s positive effect 
on EGFR signaling activation.
When considering strategies to attenuate EGFR 
signaling, there are a number of options including 
enhanced phosphatase recruitment, expression, and 
activation of receptor specific inactivating 
phosphatases and inhibition of phosphatases, such 
as SHP-2, that positively regulate signaling. How-
ever, prior to phosphatase becoming a therapeutic 
target, several important questions regarding molec-
ular mechanism must be answered. For instance, is 
the phosphatase speciﬁ  c for the EGFR or will other 
receptors also be affected? Are the tyrosines that are 
dephosphorylated going to affect signaling pathways 
required for cell growth and/or survival? Are the 
changes in phosphatase activity going to positively 
or negative regulate signaling? Nevertheless, the fact 
the modulation of phosphatase activity and expres-
sion in tissue culture models causes measurable 
changes in cell physiology, strongly supports the idea 
that phosphatases are viable therapeutic targets.
Trafﬁ  cking Mediated EGFR
Inactivation
As mentioned previously, the EGFR remains active 
during its endocytic trafﬁ  cking. Both the phos-
phorylated receptor and downstream effectors have 
been isolated from early endosomes (DiGuglielmo 
et al. 1994; Lai et al. 1989). There are two logical 
points in the late endocytic pathway in which recep-
tor inactivation may occur. The ﬁ  rst point is when 
the ligand receptor complex gets sequestered into 
the intralumenal vesicles of the MVB. This causes 
the physical separation of the receptor and down-
stream effectors. However, it is controversial as to 
whether this event functionally attenuates receptor-
mediated signaling. The second potential point of 
signal termination is the lysosomal degradation of 
the receptor. While this will clearly terminate the 
signaling process, since it follows receptor seques-
tration it may not be physiologically relevant.
EGFR sequestration
The appearance of the ligand-stimulated EGFR in 
multivesicular endosomes has been reported by 
numerous groups in a variety of cell types 
(Carpentier et al. 1987; Dunn et al. 1986; Miller 
et al. 1986). The ultrastructural analysis of liver 
carcinoma cell lines revealed stimulation with EGF 
stimulates MVB biogenesis and increases the num-
ber of internal vesicles in MVBs (White et al. 2006). 
The data indicating the liganded EGFR facilitates 
receptor sequestration into MVBs allows for the 
generation of a model in which this process sepa-
rates the receptor and effector, thereby limiting the 55
EGFR inactivation
Clinical Medicine: Oncology 2008:2 
duration of receptor signaling. Until recently, there 
were no data that indicated that the removal of the 
activated receptor from the cytosol to the intralu-
menal vesicle affected signaling. Thus, it was 
unclear whether entry into MVB was a regulatory 
mechanism for EGFR signaling or an intermediate 
step on the path to lysosomal degradation.
EGFRs destined for recycling are retained on the 
limiting membrane of the early endosome. Receptors 
that make it to the late endosome/MVB accumulate 
onto areas of the limiting membrane of the late endo-
some that invaginate and pinch off to form internal 
vesicles within the late endosome/MVB. Sequestra-
tion of the EGFR within MVBs not simply a passive 
event, as receptor activation mediates this lysosomal 
sorting through a series of highly conserved, regu-
lated, and concerted steps (Felder et al. 1990). The 
molecular identity of many of the proteins involved 
in this sorting were ﬁ  rst identiﬁ  ed in yeast genetic 
studies and are referred to as the vacuolar protein 
sorting (Vps) proteins (Katzmann et al. 2002; 
Raymond et al. 1992). The role of an increasing 
number of mammalian homologs has been con-
ﬁ  rmed in tissue culture models (Babst, 2005).
Targeting of the EGFR for degradation begins 
with the phosphorylated receptor associating with 
the E3 ubiquitin ligase c-Cbl, ubiquitylation of the 
receptor, and targeting of the receptor for degrada-
tion. Ubiquitylation of the EGFR has an established 
role in sorting the receptor for lysosomal degrada-
tion, but the role of this process in internalization 
remains controversial (Duan et al. 2003; Huang 
et al. 2006; Jiang and Sorkin, 2003). The current 
model for sorting is recognition of the ubiquitinated 
receptor by the ubiquitin-interacting motif (UIM) 
of hepatocyte growth factor-regulated tyrosine 
kinase substrate (Hrs) in complex with STAM-1 
(Bache et al. 2003; Urbe et al. 2003). Together, 
these proteins recruit related protein complexes, 
known as the ESCRT (Endosomal Sorting Com-
plex Required for Transport) complexes I, II, and 
III (Hurley and Emr, 2006). These complexes, 
along with several other highly conserved proteins, 
are responsible for directing the ligand: receptor 
complex to the intralumenal vesicles and subse-
quent lysosomal degradation (Table 1).
ESCRT mediated EGFR 
sequestration
Through mediation of MVB biogenesis and lyso-
somal sorting, proteins implicated in the late 
endocytic trafficking of the EGFR can impact 
signaling. Multiple lines of evidence, in both mam-
malian and C. elegans models, indicate the 
Cbl-mediated ubiquitination of the EGFR nega-
tively regulates EGFR signaling (Levkowitz et al. 
1999; Yoon et al. 1995). The hrs deletion mutants 
in Drosophila reveal impairment in MVB formation 
leading to sustained EGFR phosphorylation and 
MAPK activity. The phenotype of hrs deletion 
mutants is the embryonic expansion of cells depen-
dent on the EGFR during development. Therefore, 
the role of the earliest mediators of lysosomal sort-
ing in signaling is well documented, whereas the 
role of the remaining mediators is only beginning 
to be understood.
Recent studies by Bache et al. examined the 
contribution of proteins from the ESCRT-I or 
ESCRT-III complex in EGFR trafﬁ  cking and sig-
naling. Using HeLa cells as a model, two ESCRT 
proteins, Tsg101 (ESCRT-I), and Vps24 (ESCRT-
III) were independently knocked down by RNAi 
(Bache et al. 2006b). While the knockout of either 
protein caused significant delays in ligand-
stimulated receptor degradation, only knockdown 
of Tsg101 sustained EGFR signaling to the effec-
tors MEK and MAPK. Using high-resolution 
electron microscopy, the authors observed that 
knockdown of Vps24 caused the accumulation of 
the EGFR within internal vesicles of endosomes 
that appeared smaller than typical MVBs. A failure 
to sequester the EGFR and retain it on the limiting 
membrane of MVBs has been previously reported 
when TSG101 levels are depleted by RNAi (Razi 
and Futter, 2006). These results support the model 
that sorting to lumenal vesicles of late endocytic 
compartments sufficiently terminates receptor 
signaling. A link between Tsg101 function and the 
uncontrolled growth characteristic of cancer cells 
is suggested by a study in which Tsg101 was inac-
tivated by mRNA antisense transcripts, which led 
to increased colony formation in soft agar. Further 
the Tsg101 antisense transcripts, when injected into 
nude mice, increased the appearance of metastatic 
tumors (Li and Cohen, 1996).
While the work by Bache et al. provide a 
compelling argument that receptor sequestration 
is a key regulatory mechanism terminating EGFR 
signaling, there are data that contradict this model. 
Other studies suggest that signaling can be termi-
nated despite defects in intralumenal vesicle 
sequestration (Malerod et al. 2007). Depletion of 
Vps22 by siRNA in HeLa and HEp2 cells causes 56
Ceresa and Vanlandingham
Clinical Medicine: Oncology 2008:2 
a slowed EGFR degradation and accumulation of 
the receptor along the limiting membranes of the 
MVB as shown by electron microscopy and bio-
chemical analysis. However, whereas this study, 
in accordance with previous reports, showed 
TSG101 knockdown enhances EGF-dependent 
MAPK phosphorylation, Vps22 knockdown did 
not prolong MAPK activity as compared to wild 
type cells. Interestingly, the authors also found that 
lysates from Vps22 siRNA treated cells have 
reduced levels of two other ESCRT-II proteins, 
Vps25 and Vps36. Therefore, Vps22 may contribute 
to the stability of the entire complex. The signaling 
data in Vps22 depleted cells highlight the contro-
versy regarding whether receptor inactivation can 
occur upstream of intralumenal sequestration of 
the EGFR and the exact molecular role of each of 
the ESCRT complexes.
Non-ESCRT medicated EGFR 
sequestration
Proteins that are not part of the ESCRT complex 
also have been shown to play a role in EGFR 
Table 1. Role of various proteins in EGFR trafﬁ  cking and signaling.
Complex/Protein MVB  EGFR EGFR  signaling  Citation
   degradation  with  KD 
   with  KD   
ESCRT- I      
 Tsg101/Vps23  Inhibits  MVB  ↓↓↓  Sustained MAPK  (Babst et al. 2000; 
  biogenesis    activation  Bache et al. 2006b; 
        Doyette et al. 2005;
        Malerod et al. 2007; 
        Olabisi et al. 2006;
        Razi and Futter, 2006)
  VPS28/Vps28  N.D.  Inhibits degradation  N.D.  (Bishop et al. 2002)
   (antibody)
 VPS37/Vps37  N.D.  ↓↓  N.D.  (Bache et al. 2006a)
ESCRT-II      
 EAP30/Vps22  Decrease  in  ↓↓  MAPK—no  (Malerod et al. 2007)
 EGFR  ILV    change
 sequestrastion
  EAP20/Vps25  N.D.  No change (Bowers)  N.D.  (Bowers et al. 2006; 
   ↓↓ (Langelier et al.)    Langelier et al. 2006)
ESCRT-III      
 CHMP6/Vps20  N.D.  ↓  N.D.  (Langelier et al. 2006)
 CHMP3/Vps24  Decreased  ↓  MAPK—no  (Bache et al. 2006b;
  size of MVBs    change  Yan et al. 2005)
Other      
  Hrs/Vps27  Increased MVB size;      (Bache et al. 2003;
 decreased  ILVs  ↓  ↑ MAPK  Lu et al. 2003;
        Malerod et al. 2007;
        Razi and Futter, 2006)
 Rab7  N.D.  ↓↓ (dominant neg)    (Ceresa and Bahr, 2006)
   ↓↓↓(knockdown)   personal  communication
  Vps4/Vps4  Reduced # of ILVs    N.D.  (Sachse et al. 2004)
 (mutant)
 Vps34  Decreased  ILV  ↓  N.D.  (Futter et al. 2001)
 formation
  UBPY/Doa4  Increased # and  ↓↓  N.D.  (Row et al. 2006)
  size of MVB; 
 fewer  ILVs
 LIP5/Vtal  N.D.  ↓↓↓  N.D.  (Ward et al. 2005)
Notes: Shown in a partial listing of proteins that have been shown to have a role in EGFR trafﬁ  cking through the late endocytic pathway. 
N.D. = not determined. Downward arrows represent the change in EGFR degradation kinetics. ↓↓↓, ↓↓, and ↓ indicate an increase in the 
half-life of ligand-stimulated EGFR by >5-fold, 3–4 fold, and 1–2 fold, respectively.  Unless otherwise noted, studies were done by 
knocking down protein expression. # refers to the number.  ILV = Intralumenal vesicles.57
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intralumenal sequestration. For instance, the EGFR 
effector annexin-1 has been shown to be required 
for sequestration (Futter et al. 1993). Despite the 
failure of the EGFR to internalize into vesicles 
within the MVB in annexin-1 mouse knockout 
cells, the EGFR is still efﬁ  ciently degraded, albeit 
with a minor delay in the rate of degradation (White 
et al. 2006). The authors suggest that internal 
vesicle formation is not necessary for EGFR 
degradation, but makes the degradation process 
more efﬁ  cient. Thus, entry of receptors into limit-
ing membranes of the MVB may in fact be to 
sequester the receptor rather than simply as an 
intermediate in the degradation pathway. Similar 
results have been seen with the knockdown of 
Vps34, a PI-3 kinase, in HEp-2 cells (Futter et al. 
2001). Like the annexin-1 knockout, the active 
EGFR is retained on the limiting membrane of the 
late endocytic compartment and there is only a 
slight delay in the rate of delivery to lysosomes. 
Examination of the tyrosine-phosphorylation of 
downstream effectors in Vps34 knockdown cells 
revealed enhanced phosphorylation of several 
proteins. One implication of these ﬁ  ndings is that 
there are two possible points of inactivation in the 
late endocytic pathway since, in the absence of 
sequestration-mediated inactivation, lysosomal 
delivery functions as the mechanism of receptor 
inactivation.
EGFR degradation
There is evidence that sequestration of the EGFR 
is not sufﬁ  cient for terminating the signaling 
capability of the EGFR and lysosomal degrada-
tion is the rate-limiting step in receptor inactiva-
tion. Oksvold et al. prevented lysosomal degradation 
using inhibitors of lysosomal enzymes or blocked 
trafﬁ  cking to lysosome using the lysosomotropic 
amine chloroquine (Oksvold et al. 2001). Immu-
noblots of subcellular fractions isolated over 
gradients revealed the accumulation of activated 
EGFR and MAPK within the same fraction. 
Immunoelectron microspcopy revealed the major-
ity of phosphorylated EGFR accumulated intra-
lumenally, with a small fraction present on the 
cytosolic membrane. Immunoﬂ  uorescent staining 
of cells treated with chloroquine or lysosomal 
inhibitors showed co-localization of the adaptor 
proteins Shc, Grb2, and Cbl with phosphorylated 
EGFR indicating the potential for signaling 
existed. These proteins accumulated in MVB as 
deﬁ  ned by the presence of MVB markers CD63 
and LAMP-1, and exclusion of the early endo-
some marker EEA1. Immunoblot analysis of 
phosphorylated EGFR and MAPK revealed cells 
stimulated with EGF and chased with chloroquine 
for 120’, but not untreated cells, sustained their 
activity at time points that electron microscopy 
revealed to be consistent with EGFR localization 
in MVBs . These data indicate that in the absence 
of lysosomal delivery, activated receptor can 
accumulate in MVBs and signal to downstream 
effectors.
In the pharmacologically treated cells, immu-
noelectron microscopy revealed the majority of 
phosphorylated receptors accumulated in internal 
vesicles of the MVB. It is a formal possibility that 
sustained signaling was due to the fraction 
remaining on the limiting membrane. EGF stim-
ulation substantially increases the volume of 
cytosol containing MVBs (Futter et al. 1998; 
White et al. 2006); suggesting proteins other than 
the EGFR, such as downstream effectors, could 
be removed from the cytosol and delivered for 
degradation. Therefore, the presence of an acti-
vated effector is not definitive evidence that 
physiologic signaling is occurring. Further anal-
ysis of downstream signaling events, such as DNA 
transcription, cell viability, and cell motility is 
needed to establish whether the active effectors 
modulate cell biology.
The molecular regulation of EGFR signaling in 
the late endocytic pathway remains unclear. Spe-
ciﬁ  cally, determining whether the terminal step in 
EGFR signaling is mediated through receptor 
sequestration or degradation will aid in the design 
and use of therapeutic agents. To date, the majority 
of studies have focused on disrupting the sequestra-
tion/degradation process. As a strategy to terminate 
hyperactive EGFR signaling, it will be more useful 
to accelerate these trafﬁ  cking events and examine 
the biochemical (effector activity) and physiolog-
ical (cell biology) consequences. These ﬁ  ndings 
will determine the potential of the late endocytic 
pathway as a therapeutic target.
Concluding Remarks
Clinical and experimental data indicate that the 
EGFR is a viable target to inhibit the growth of 
non-transformed and transformed cells. Monoclo-
nal antibodies targeting the EGFR and tyrosine 
kinase inhibitors have both demonstrated success 58
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in inhibiting the growth of cancerous and 
non-cancerous cells. However, there still remain a 
number of cancers characterized by EGFR 
overexpression that are refractory to these 
therapies. Rather than strive to make better inhib-
itors of EGFR activity, we suggest the alternative 
approach of looking for ways to accelerate the 
inactivation of the EGFR once it becomes stimu-
lated. This strategy would have the greatest effect 
on those cells with the highest levels of EGFR 
expression and EGFR activation. As the biochem-
ical details of the pathways that lead to receptor 
inactivation are elucidated, it allows one to cre-
atively think about how this information can be 
used in anti-cancer-therapies.
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